ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROELLIG, Andreas PETZOLD, Tim SAUER, Sebastian SCHOLL, Andreas HOCHHAUS, Martina CRYSANDT, Tim H BRUEMMENDORF, Ralph NAUMANN, Bjoern STEFFEN, Volker KUNZMANN, Hermann EINSELE, Markus SCHAICH, Andreas BURCHERT, Andreas NEUBAUER, Kerstin SCHAEFER-ECKART, Christoph SCHLIEMANN, Stefan W KRAUSE, Regina HERBST, Mathias HAENEL, Maher HANOUN, Ulrich KAISER, Martin KAUFMANN, Zdeněk RÁČIL, Jiří MAYER, Uta OELSCHLAEGEL, Wolfgang E BERDEL, Gerhard EHNINGER, Hubert SERVE, Carsten MUELLER-TIDOW, Uwe PLATZBECKER, Claudia D BALDUS, Andreas DAHL, Johannes SCHETELIG, Martin BORNHAEUSER, Jan Moritz MIDDEKE a Christian THIEDE. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia. Leukemia. London: Nature Publishing Group, 2023, roč. 37, č. 12, s. 2395-2403. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-023-02061-1.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Autoři ECKARDT, Jan-Niklas, Sebastian STASIK, Christoph ROELLIG, Andreas PETZOLD, Tim SAUER, Sebastian SCHOLL, Andreas HOCHHAUS, Martina CRYSANDT, Tim H BRUEMMENDORF, Ralph NAUMANN, Bjoern STEFFEN, Volker KUNZMANN, Hermann EINSELE, Markus SCHAICH, Andreas BURCHERT, Andreas NEUBAUER, Kerstin SCHAEFER-ECKART, Christoph SCHLIEMANN, Stefan W KRAUSE, Regina HERBST, Mathias HAENEL, Maher HANOUN, Ulrich KAISER, Martin KAUFMANN, Zdeněk RÁČIL (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), Uta OELSCHLAEGEL, Wolfgang E BERDEL, Gerhard EHNINGER, Hubert SERVE, Carsten MUELLER-TIDOW, Uwe PLATZBECKER, Claudia D BALDUS, Andreas DAHL, Johannes SCHETELIG, Martin BORNHAEUSER, Jan Moritz MIDDEKE a Christian THIEDE.
Vydání Leukemia, London, Nature Publishing Group, 2023, 0887-6924.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 11.400 v roce 2022
Kód RIV RIV/00216224:14110/23:00132558
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/s41375-023-02061-1
UT WoS 001085283400001
Klíčová slova anglicky Acute myeloid leukaemia; Risk factors
Štítky 14110212, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 2. 2. 2024 13:05.
Anotace
Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found IKZF1 alterations in 45 cases with a mutational hotspot at N159S. AML with mutated IKZF1 was associated with alterations in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6, while alterations of NPM1, TET2, FLT3-ITD, and normal karyotypes were less frequent. The clinical phenotype of IKZF1-mutated AML was dominated by anemia and thrombocytopenia. In both univariable and multivariable analyses adjusting for age, de novo and secondary AML, and ELN2022 risk categories, we found mutated IKZF1 to be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival. The deleterious effects of mutated IKZF1 also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (n = 519) in both univariable and multivariable models. These dismal outcomes are only partially explained by the hotspot mutation N159S. Our findings suggest a role for IKZF1 mutation status in AML risk modeling.
VytisknoutZobrazeno: 18. 7. 2024 15:42